Archives for Blogs

Delivering the potential of cancer genomics to patients

This week Nonacus Ltd announced a partnership with Dante Labs and Cambridge Cancer Genomics which aims to build the most comprehensive and patient-centric tumour profiling service enabling improved cancer patient management, treatment and monitoring.
Read More

Nonacus wins Government grant to validate rapid sequencing based surveillance testing for COVID-19.

Nonacus was recently awarded an Innovate UK grant, to validate a novel, rapid method for sequencing respiratory viral genomes using nanopore sequencing. This method will provide more comprehensive information about the Sars-CoV-2 genome to support a post pandemic world and, with a respiratory viral panel in the pipeline, will provide surveillance of other respiratory diseases too. So, if your cough is not due to COVID-19, you will be able to find out which respiratory virus is causing it.
Read More

No Gluten Required

Nonacus scientists, together with researchers at the University of Cambridge, are working on the development of a novel, non-invasive test for coeliac disease that works even if the patient is already on a gluten-free diet.
Read More

Covid-19. Can we help?

The impact of the coronavirus is being felt right across the UK and I hope that you, your family and your friends remain safe and well. With yesterday’s announcement from the government, we know that this impact will be wide ranging and may be having a knock on effect on your laboratory. We are hearing of laboratory closures during the self-isolation period and labs operating with a skeleton staff, all of which puts pressure on laboratory services.
Read More

Nonacus introduces ExomeCG product to simplify molecular and cytogenomics data generation and interpretation

Birmingham, UK, 16 October 2019: Nonacus Ltd, a UK based precision medicine company and manufacturer of ultra-sensitive next-generation sequencing (NGS) products, has announced the launch of ExomeCG, a new product to simplify the generation and interpretation of molecular and cytogenomic data. The new product has been co-developed with digital health technology company, Congenica Ltd, which specialises in software solutions that enable accelerated interpretation of complex genomic data to improve disease diagnosis.
Read More

New QA / QC Production Scientist Role at Nonacus

We are excited to announce that Nonacus are recruiting! Following the successful launch of our Cell3TM DNA product range we are now growing the team and are seeking a highly motivated experienced Quality Assurance (QA) / Quality Control (QC) Production Scientist to join our team. The full job description and details on how to apply...
Read More

Nonacus works with leading NHS laboratory on validating innovative product

New direct from plasma cfDNA test provides results in three hours. Since 2011 the NHS has been using cell free DNA (cfDNA) in fetal sex testing to identify pregnancies at high risk of sex-linked disorders. This test is done by extracting cfDNA from maternal plasma: a process that is slowing down results for patients.
Read More

NIPD of fetal RhD takes step closer to EQA

Nonacus reviews latest accreditation efforts. Currently, the RhD genotyping landscape doesn’t feature a full EQA (European Quality Assurance) scheme but this latest report published in Blood Transfusion represents a big step forward towards an EQA. The authors have set themselves an objective to implement a regular EQA scheme through their working group. Chris Sale- CEO
Read More

Why cfDNA has caused a revolution in genetic diagnostics

There’s been a revolution. It comes in the form of cell free DNA (cfDNA), which is changing patient pathways for the better across the globe. Due to its nature, cfDNA is considered as an excellent biomarker and source of genetic information. Cell free DNA is thought to originate predominantly from cells that undergo programmed cell...
Read More